[Treatment of primary hyperlipoproteinemia type II B with diet and niamide]. 1977

Z Plamieniak, and E Szklarz, and M Stepien-Dobrowolska, and A Milewicz

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009526 Nialamide An MAO inhibitor that is used as an antidepressive agent.
D004035 Diet Therapy Adjusting the quantity and quality of food intake to improve health status of an individual. This term does not include the methods of food intake (NUTRITIONAL SUPPORT). Diet Therapy, Restrictive,Dietary Modification,Dietary Restriction,Restriction Diet Therapies,Restriction Diet Therapy,Restrictive Diet Therapies,Restrictive Diet Therapy,Diet Modification,Therapy, Diet,Diet Modifications,Diet Therapies,Diet Therapies, Restriction,Diet Therapy, Restriction,Dietary Modifications,Dietary Restrictions,Modification, Diet,Modification, Dietary,Restriction, Dietary,Therapy, Restriction Diet,Therapy, Restrictive Diet
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000960 Hypolipidemic Agents Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. Antihyperlipidemic,Antilipemic,Antilipemic Agents,Antilipemic Drug,Hypolipidemic Agent,Hypolipidemic Drug,Antihyperlipemics,Antihyperlipidemics,Antilipemic Drugs,Antilipemics,Hypolipidemic Drugs,Agent, Hypolipidemic,Agents, Antilipemic,Agents, Hypolipidemic,Drug, Antilipemic,Drug, Hypolipidemic,Drugs, Antilipemic,Drugs, Hypolipidemic

Related Publications

Z Plamieniak, and E Szklarz, and M Stepien-Dobrowolska, and A Milewicz
July 1974, American journal of diseases of children (1960),
Z Plamieniak, and E Szklarz, and M Stepien-Dobrowolska, and A Milewicz
December 1979, International journal of clinical pharmacology and biopharmacy,
Z Plamieniak, and E Szklarz, and M Stepien-Dobrowolska, and A Milewicz
May 1978, La Nouvelle presse medicale,
Z Plamieniak, and E Szklarz, and M Stepien-Dobrowolska, and A Milewicz
January 1976, Pediatrics,
Z Plamieniak, and E Szklarz, and M Stepien-Dobrowolska, and A Milewicz
November 1973, Pediatrics,
Z Plamieniak, and E Szklarz, and M Stepien-Dobrowolska, and A Milewicz
September 1976, Atherosclerosis,
Z Plamieniak, and E Szklarz, and M Stepien-Dobrowolska, and A Milewicz
April 1971, Clinical science,
Z Plamieniak, and E Szklarz, and M Stepien-Dobrowolska, and A Milewicz
April 1973, Die Medizinische Welt,
Z Plamieniak, and E Szklarz, and M Stepien-Dobrowolska, and A Milewicz
March 1981, Chest,
Z Plamieniak, and E Szklarz, and M Stepien-Dobrowolska, and A Milewicz
January 1973, Advances in experimental medicine and biology,
Copied contents to your clipboard!